Diabetes, Vol 46, Issue 2 265-270, Copyright © 1997 by American Diabetes Association

ARTICLES

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group

JH Anderson, RL Brunelle, VA Koivisto, A Pfutzner, ME Trautmann, L Vignati and R DiMarchi
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA.

Insulin lispro, an insulin analog recently developed particularly for mealtime therapy, has a fast absorption rate and a short duration of action. We compared insulin lispro and regular human insulin in the mealtime treatment of 1,008 patients with IDDM. The study was a 6-month randomized multinational (17 countries) and multicenter (102 investigators) clinical trial performed with an open-label crossover design. Insulin lispro was injected immediately before the meal, and regular human insulin was injected 30-45 min before the meal. Throughout the study, the postprandial rise in serum glucose was significantly lower during insulin lispro therapy. At the endpoint, the postprandial rise in serum glucose was reduced at 1 h by 1.3 mmol/l and at 2 h by 2.0 mmol/l in patients treated with insulin lispro (P < 0.001). The rate of hypoglycemia was 12% less with insulin lispro (6.4 +/- 0.2 vs. 7.2 +/- 0.3 episodes/30 days, P < 0.001), independent of basal insulin regimen or HbA1c level. The reduction was observed equally in episodes with and without symptoms. When the total number of episodes for each patient was analyzed according to the time of occurrence, the number of hypoglycemic episodes was less with insulin lispro than with regular human insulin therapy during three of four quarters of the day (P < 0.001). The largest relative improvement was observed at night. In conclusion, insulin lispro improves postprandial control, reduces hypoglycemic episodes, and improves patient convenience, compared with regular human insulin, in IDDM patients.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. Jovanovic and D. J. Pettitt Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224. [Full Text] [PDF]

				C. C. Lubitz, J. J. Seley, C. Rivera, N. Sinha, and D. J. Brillon The Perils of Inpatient Hyperglycemia Management: How We Turned Apathy Into Action Diabetes Spectr, January 1, 2007; 20(1): 18 - 21. [Abstract] [Full Text] [PDF]

				J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]

				I. B. Hirsch, B. W. Bode, S. Garg, W. S. Lane, A. Sussman, P. Hu, O. M. Santiago, J. W. Kolaczynski, and for the Insulin Aspart CSII/MDI Comparison Study G Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII Diabetes Care, March 1, 2005; 28(3): 533 - 538. [Abstract] [Full Text] [PDF]

				A. M. Hennige, R. Lehmann, C. Weigert, K. Moeschel, M. Schauble, E. Metzinger, R. Lammers, and H.-U. Haring Insulin Glulisine: Insulin Receptor Signaling Characteristics In Vivo Diabetes, February 1, 2005; 54(2): 361 - 366. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				C. L. Thompson, K. C. Dunn, M. C. Menon, L. E. Kearns, and S. S. Braithwaite Hyperglycemia in the Hospital Diabetes Spectr, January 1, 2005; 18(1): 20 - 27. [Abstract] [Full Text] [PDF]

				K. B. Campbell and S. S. Braithwaite Hospital Management of Hyperglycemia Clin. Diabetes, April 1, 2004; 22(2): 81 - 88. [Full Text] [PDF]

				S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]

				C. Homko, A. Deluzio, C. Jimenez, J. W. Kolaczynski, and G. Boden Comparison of Insulin Aspart and Lispro: Pharmacokinetic and metabolic effects Diabetes Care, July 1, 2003; 26(7): 2027 - 2031. [Abstract] [Full Text] [PDF]

				R. Boskovic, D. S. Feig, L. Derewlany, B. Knie, G. Portnoi, and G. Koren Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies Diabetes Care, May 1, 2003; 26(5): 1390 - 1394. [Abstract] [Full Text] [PDF]

				R. R. Henry, S. R.D. Mudaliar, W. C. Howland III, N. Chu, D. Kim, B. An, and R. R. Reinhardt Inhaled Insulin Using the AERx Insulin Diabetes Management System in Healthy and Asthmatic Subjects Diabetes Care, March 1, 2003; 26(3): 764 - 769. [Abstract] [Full Text] [PDF]

				M. Kalergis, A. Schiffrin, R. Gougeon, P. J.H. Jones, and J.-F. Yale Impact of Bedtime Snack Composition on Prevention of Nocturnal Hypoglycemia in Adults With Type 1 Diabetes Undergoing Intensive Insulin Management Using Lispro Insulin Before Meals: A randomized, placebo-controlled, crossover trial Diabetes Care, January 1, 2003; 26(1): 9 - 15. [Abstract] [Full Text] [PDF]

				S. E. Fineberg, J. Huang, R. Brunelle, K. S. Gulliya, and J. H. Anderson Jr Effect of Long-Term Exposure to Insulin Lispro on the Induction of Antibody Response in Patients With Type 1 or Type 2 Diabetes Diabetes Care, January 1, 2003; 26(1): 89 - 96. [Abstract] [Full Text] [PDF]

				A. M.E. Stades, J. B.L. Hoekstra, I. van den Tweel, D. W. Erkelens, and F. Holleman Additional Lunchtime Basal Insulin During Insulin Lispro Intensive Therapy in a Randomized, Multicenter, Crossover Study in Adults : A real-life design Diabetes Care, April 1, 2002; 25(4): 712 - 717. [Abstract] [Full Text] [PDF]

				J. D. Meece and R. K. Campbell Insulin Lispro Update The Diabetes Educator, March 1, 2002; 28(2): 269 - 277. [Abstract] [PDF]

				D. R Elbourne, D. G Altman, J. P. Higgins, F. Curtin, H. V Worthington, and A. Vail Meta-analyses involving cross-over trials: methodological issues Int. J. Epidemiol., February 1, 2002; 31(1): 140 - 149. [Abstract] [Full Text] [PDF]

				K. L. Herbst and I. B. Hirsch Insulin Strategies for Primary Care Providers Clin. Diabetes, January 1, 2002; 20(1): 11 - 17. [Abstract] [Full Text] [PDF]

				E. Bonora, F. Calcaterra, S. Lombardi, N. Bonfante, G. Formentini, R. C. Bonadonna, and M. Muggeo Plasma Glucose Levels Throughout the Day and HbA1c Interrelationships in Type 2 Diabetes: Implications for treatment and monitoring of metabolic control Diabetes Care, December 1, 2001; 24(12): 2023 - 2029. [Abstract] [Full Text] [PDF]

				L. C. Deeb, J. H. Holcombe, R. Brunelle, S. Zalani, S. Brink, M. Jenner, H. Kitson, K. Perlman, and M. Spencer Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes Pediatrics, November 1, 2001; 108(5): 1175 - 1179. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				M. Saleh and G. Grunberger Hypoglycemia: An Excuse for Poor Glycemic Control? Clin. Diabetes, October 1, 2001; 19(4): 161 - 167. [Abstract] [Full Text] [PDF]

				E. Tsui, A. Barnie, S. Ross, R. Parkes, and B. Zinman Intensive Insulin Therapy With Insulin Lispro: A randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection Diabetes Care, October 1, 2001; 24(10): 1722 - 1727. [Abstract] [Full Text] [PDF]

				A. Bhattacharyya, S. Brown, S. Hughes, and P.A. Vice Insulin lispro and regular insulin in pregnancy QJM, May 1, 2001; 94(5): 255 - 260. [Abstract] [Full Text] [PDF]

				P. J. Beisswenger, S. K. Howell, R. M. O’Dell, M. E. Wood, A. D. Touchette, and B. S. Szwergold {alpha}-Dicarbonyls Increase in the Postprandial Period and Reflect the Degree of Hyperglycemia Diabetes Care, April 1, 2001; 24(4): 726 - 732. [Abstract] [Full Text]

				J. H. Silverstein and A. L. Rosenbloom New Developments in Type 1 (Insulin-Dependent) Diabetes Clinical Pediatrics, May 1, 2000; 39(5): 257 - 266. [Abstract] [PDF]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				B. Guerci, L. Meyer, A. Sallé, A. Charrié, B. Dousset, O. Ziegler, and P. Drouin Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2673 - 2678. [Abstract] [Full Text]

				R. R. Bowsher, R. A. Lynch, P. Brown-Augsburger, P. F. Santa, W. E. Legan, J. R. Woodworth, and R. E. Chance Sensitive RIA for the Specific Determination of Insulin Lispro Clin. Chem., January 1, 1999; 45(1): 104 - 110. [Abstract] [Full Text] [PDF]

				R. K. Campbell, D. A. Sclar, L. M. Robison, J. K. Stowers, J. C. Ferguson, B. S. Trippe, and D. M. Kayne Impact on Clinical. Status and Quality of Life of Switching From Regular Insulin to Insulin Lispro Among Patients Using Insulin Pumps The Diabetes Educator, January 1, 1998; 24(1): 95 - 99. [PDF]

				K. S. Rutledge, H. P. Chase, G. J. Klingensmith, P. A. Walravens, R. H. Slover, and S. K. Garg Effectiveness of Postprandial Humalog in Toddlers With Diabetes Pediatrics, December 1, 1997; 100(6): 968 - 972. [Abstract] [Full Text] [PDF]

				T. Diamond, N. Kormas, J. H. Anderson, E. J. Bastyr, and K. L. Wishner Possible Adverse Fetal Effect of Insulin Lispro N. Engl. J. Med., October 2, 1997; 337(14): 1009 - 1010. [Full Text]

				{blacktriangledown}Humalog - a new insulin analogue DTB, August 1, 1997; 35(8): 57 - 58. [Abstract] [Full Text] [PDF]

				F. Holleman and J. B.L. Hoekstra Insulin Lispro N. Engl. J. Med., July 17, 1997; 337(3): 176 - 183. [Full Text] [PDF]